Completed
PHASE2
INTERVENTIONAL
NCT06326060
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Interventions
Name:
NNC0519-0130
Type:
DRUG
Description:
NNC0519-0130 will be administered subcutaneously.
Name:
Placebo
Type:
DRUG
Description:
Placebo will be administered subcutaneously.
Name:
Tirzepatide
Type:
DRUG
Description:
Tirzepatide will be administered subcutaneously.
Primary Outcomes
Measure:
Relative change in body weight
TimeFrame:
From baseline (week 0) to end of treatment (week 36)
Description:
Measured in percentage of body weight.
Trial Information
NCT ID
NCT06326060
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025